HealthLeaders Media March 19, 2019
Steven Porter

The decision to leave the agency did not come easily, but the commissioner said he feels good about where things are headed and who’s in charge.

KEY TAKEAWAYS

Gottlieb said the partial government shutdown that ended in January was ‘the biggest operational challenge we faced in modern times.’

He expressed confidence in the FDA’s trajectory, including its approach to biosimilars.

His final day on the job is expected to be Friday, April 5, after he testifies before Congress about the fiscal year 2020 budget proposal.

Scott Gottlieb, MD, the outgoing commissioner of the Food and Drug Administration, expressed confidence Tuesday in where the agency is headed as he prepares to leave his post in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: FDA, Govt Agencies
Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
FDA approves Akebia anemia pill, two years after rejection
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension
FDA approves Merck drug for rare lung disorder
Neuronetics wins FDA clearance for device to treat adolescents with depression

Share This Article